Legend Biotech, a leading global cell therapy company, has announced the forthcoming presentation of new and updated data from its CARTITUDE clinical development program at the 2024 American Society of…
Eisai has announced its participation in the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO24), held both virtually and in-person in Chicago, Illinois from May 31 to June…
UCB, a leading global biopharmaceutical company, has announced the publication of results from the Phase 3 BE HEARD I and BE HEARD II trials in The Lancet. These trials evaluated…
A global oncology company today announced the presentation of new analyses for BRUKINSA® (zanubrutinib) at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 31 to…
Clinical Trials Day is globally recognized on May 20, and this year, the Walgreens Clinical Trials team celebrated with a special event dedicated to women’s health. Appropriately, May is National…
First-in-human data for the potential first-in-class anti-CEACAM5 ADC with topoisomerase 1 inhibitor payload, M9140, in the treatment of metastatic colorectal cancer to be featured in an oral presentation. Phase I…
Eli Lilly and Company announced today a significant increase in investment for its Lebanon, Indiana, manufacturing site. The company has committed an additional $5.3 billion, bringing the total investment to…
Today, Astellas announced the signing of a memorandum of understanding with YASKAWA Electric Corporation (YASKAWA), marking the beginning of discussions toward creating an innovative cell therapy ecosystem. This collaboration aims…
CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) have announced the publication of groundbreaking findings in Nature Communications, revealing the results from a comprehensive phase 1/2/3a/3b study investigating the safety,…
Aetna Better Health of Virginia, a CVS Health® company, has pledged $400,000 to Restoration Housing to facilitate the acquisition of a property in Roanoke, Virginia. This property will be utilized…
Bristol Myers Squibb (NYSE: BMY) has unveiled the Live Your PosSCZible campaign, a nationwide initiative developed in collaboration with the schizophrenia community. The campaign aims to amplify firsthand experiences and…
Bristol Myers Squibb (NYSE: BMY) has unveiled the Live Your PosSCZible campaign, a nationwide initiative in collaboration with the schizophrenia community. The campaign aims to amplify personal experiences, offering educational…